Safety and Feasibility Study of the Shockwave Lithoplasty System
To study the early safety and performance of the Shockwave Medical System in subjects to demonstrate that the device can safely and effectively deliver localized energy for the treatment of vascular disease.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Safety and Feasibility Study of the Shockwave Lithoplasty System|
- Safety determined by 30day New-Onset Serious Adverse Events [ Time Frame: 30 day ] [ Designated as safety issue: Yes ]New Onset Serious Adverse Events (SAE) include death, device-related surgery or repeat hospitalization, occlusion, or major unplanned amputation through 30 days following the procedure.
- Angiographic Success as measured by residual stenosis <30% reference vessel. [ Time Frame: Peri-Procedural ] [ Designated as safety issue: No ]
|Study Start Date:||August 2012|
|Study Completion Date:||August 2014|
|Primary Completion Date:||August 2014 (Final data collection date for primary outcome measure)|
Experimental: Lithotripsy Treatment
Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.
Device: Shockwave System Treatment
Shockwave System Treatment during vascular disease intervention.
Shockwave Medical, Inc. intends to conduct a prospective, single-arm, single-center, First in Human study designed to evaluate the early safety and feasibility of the Shockwave Lithoplasty System in subjects with heavily calcified infrainguinal arteries with 3.75mm to 6mm reference vessel diameter at target site. The Shockwave Lithoplasty System is indicated to generate sonic shockwave energy within the target treatment site and disrupt calcium within the lesion to allow for subsequent dilation of a peripheral artery stenosis using low balloon pressure. Up to 10 subjects will be enrolled to undergo lihtoplasty.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01577888
|Auckland City Hospital|
|Auckland, New Zealand, 92024|
|Principal Investigator:||Andrew Holden, MD||Auckland City Hospital|